Effect of Cancer Antigen-125 Elimination Rate Constant K and BRCA Mutation Status on the Prognosis of Interval Debulking Surgery in Advanced High-Grade Serous Ovarian Cancer
Abstract
Objective
To investigate the predictive value of the cancer antigen-125 elimination rate constant K (KELIM) for treatment response and prognosis in patients with advanced high-grade serous ovarian cancer (HGSOC) undergoing neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS), and to analyze the combined prognostic significance of KELIM and the mutation status of breast cancer susceptibility gene (BRCA).
Methods
A total of 106 patients with advanced HGSOC who had undergone NACT-IDS were retrospectively enrolled. The KELIM values during neoadjuvant chemotherapy were calculated, and patients were divided into high- and low-KELIM groups using a cutoff value of 1.0. Clinicopathological characteristics, R0 resection rates, and platinum sensitivity rates were compared between the two groups. Logistic regression analysis was performed to identify predictive factors for R0 resection, while Kaplan-Meier survival analysis and Cox proportional hazards regression were performed to evaluate factors associated with progression-free survival (PFS). Furthermore, the patients were stratified according to both KELIM and BRCA status to assess the risk of platinum-resistant recurrence in each subgroup.
Results
The R0 resection rate was higher in the KELIM ≥ 1 group than in the KELIM < 1 group (77.1% vs 55.2%), and the difference was statistically significant (P = 0.024). Multivariate logistic regression analysis showed that KELIM was an independent predictor of R0 resection (odds ratio [OR] = 2.922, 95% CI: 1.112–7.678). Survival analysis demonstrated longer PFS in the KELIM ≥1 group compared with that in the KELIM <1 group (33.0 months vs 18.0 months), and the difference was statistically significant (P < 0.001). Multivariate Cox regression analysis showed that KELIM ≥ 1 was associated with a reduced risk of disease progression (hazard ratio [HR] = 0.481, 95% CI: 0.280-0.826). Combined stratification analysis revealed that no platinum-resistant recurrence was observed in the subgroup with both KELIM ≥1 and a BRCA-positive status (0/21). Compared with patients with KELIM <1 and a BRCA-negative status, this subgroup exhibited a lower risk of platinum-resistant recurrence (OR = 0.053, 95% CI: 0.003-0.932, P = 0.006).
Conclusion
KELIM is an effective dynamic biomarker for predicting surgical outcomes and PFS in patients undergoing NACT-IDS. Combined stratification by KELIM and BRCA status allows more precise identification of the patient population with both KELIM ≥1 and BRCA-positive status, who have an extremely low risk of platinum-resistant recurrence, thereby providing an important basis for individualized treatment and risk stratification management in patients with advanced HGSOC.
Keywords: High-grade serous ovarian cancer, Interval debulking surgery, Neoadjuvant chemotherapy, Cancer antigen-125 elimination rate constant K, BRCA gene
Full Text:
PDFReferences
Gaillard S, Lacchetti C, Armstrong D K, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update[J]. J Clin Oncol, 2025, 43(7): 868. DOI: 10.1200/JCO-24-02589.
Nag S, Ray Coquard I, Gupta S, et al. Pan-asia adapted ESMO clinical practice guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer[J/OL]. ESMO Open, 2025, 10(6): 105125. https://www.esmoopen.com/article/S2059-7029(25)00994-9/fulltext. DOI: 10.1016/j.esmoop.2025.105125.
González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(10): 833. DOI: 10.1016/j.annonc.2023.07.011.
Kim J H, Cho H W, Park E Y, et al. Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis[J]. Int J Gynecol Cancer, 2023, 33(12): 1913. DOI: 10.1136/ijgc-2023-004825.
Zebic D S, Tjokrowidjaja A, Francis K E, et al. Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer[J]. Br J Cancer, 2024, 130(3): 425. DOI: 10.1038/s41416-023-02528-z.
You B, Colomban O, Heywood M, et al. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)[J]. Gynecol Oncol, 2013, 130(2): 289. DOI: 10.1016/j.ygyno.2013.05.013.
Colomban O, Swisher E M, Kristeleit R, et al. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10[J/OL]. EBioMedicine, 2023, 89: 104477. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00042-7/fulltext. DOI: 10.1016/j.ebiom.2023.104477.
Corbaux P, You B, Glasspool R M, et al. Survival and modelled cancer antigen-125 ELIMination rate constant k score in ovarian cancer patients in first-line before poly (ADP-ribose) polymerase inhibitor era: a gynaecologic cancer intergroup meta-analysis[J/OL]. Eur J Cancer, 2023, 191: 112966. https://www.ejcancer.com/article/S0959-8049(23)00318-0/fulltext. DOI: 10.1016/j.ejca.2023.112966.
Van Wagensveld L, Colomban O, Van der Aa M A, et al. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting” [J/OL]. J Gynecol Oncol, 2024, 35(3): e34. https://doi.org/10.3802/jgo. 2024.35.e34.
Kamm M, Hildebrandt F, Titze B, et al. Ex vivo fluorescence confocal microscopy for intraoperative examinations of lung tumors as alternative to frozen sections: a proof-of-concept study[J/OL]. Cancers (Basel), 2024, 16(12): 2221. https://doi.org/10.3390/cancers16122221.
Ambrosino F A, Pisano C, Napoli M D, et al. KELIM score: a marker of chemosensitivity in ovarian cancer[J/OL]. Cancer Treat Rev, 2026, 143: 103071. https://www.cancertreatmentreviews.com/article/S0305-7372(25) 00193-8/abstract. DOI: 10.1016/j.ctrv.2025.103071.
Jiang S, Zhu J, Wang Y Y, et al. Evaluating the prognostic value of KELIM and BRCAmutation status in advanced highgrade serous ovariancancer[J]. Progress in Obstetrics and Gynecology, 2025, 34(3): 185. DOI: 10.13283/j.cnki.xdfckjz.2025. 03.031.
St Laurent J, Liu J F. Treatment approaches for platinum-resistant ovarian cancer[J]. J Clin Oncol, 2024, 42(2): 127. DOI: 10.1200/JCO.23.01771.
You B, Robelin P, Tod M, et al. CA-125 ELIMination rate constant k (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase Ⅱ CHⅣA trial[J]. Clin Cancer Res, 2020, 26(17): 4625. DOI: 10.1158/1078-0432.CCR-20-0054.
You B, Sehgal V, Hosmane B, et al. CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA/GOG-3005 study[J]. J Clin Oncol, 2023, 41(1): 107. DOI: 10.1200/JCO.22.00430.
LI C, CUI Q, WANG X, et al. CA-125 elimination rate constant k (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two chinese hospitals[J/OL]. BMC Cancer, 2024, 24(1): 609. https://pmc.ncbi.nlm.nih.gov/articles/PMC11107035/. DOI: 10.1186/s12885-024-12252-3.
Bouvarel B, Colomban O, Frenel J S, et al. Clinical impact of CA-125 ELIMination rate constant k (KELIM) on surgical strategy in advanced serous ovarian cancer patients[J]. Int J Gynecol Cancer, 2024, 34(4): 574. DOI: 10.1136/ijgc-2023-004872.
Zouzoulas D, Tsolakidis D, Tzitzis P, et al. The use of CA-125 KELIM to identify which patients can achieve complete cytoreduction after neoadjuvant chemotherapy in high-grade serous advanced ovarian cancer[J/OL]. Cancers (Basel), 2024, 16(7): 1266. https://doi.org/10.3390/cancers16071266.
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018, 379(26): 2495. DOI: 10.1056/NEJMoa1810858.
Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial[J]. Ann Oncol, 2023, 34(8): 681. DOI: 10. 1016/j.annonc.2023.05.005.
Refbacks
- There are currently no refbacks.
